Shuttle Pharmaceuticals (SHPH) announced a sponsored research agreement with the University of California, San Francisco, UCSF, to advance pre-clinical development of Shuttle Diagnostics’ ligand to the prostate-specific membrane antigen, PSMA, as a potential diagnostic and therapeutic, or theranostic, molecule. Theranostic molecules are suitable for diagnosis and therapy of cancers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH: